adverse effects were gastrointestinal in nature, similar to GLP1 receptor agonists 9
No participants developed antibodies against AOD-9604, and no treatment-related serious adverse events led to study withdrawal
Difficult tradeoffs exist for patients and plan sponsors alike. Faust added, We anticipate demand for GLP-1s will only increase in coming years
The STEP (Semaglutide Treatment Effect in People with obesity) trial program showed that participants using semaglutide 2.4 mg weekly achieved an average weight loss of 12-15% of their initial body weight over 68 weeks, compared to 2-3% with placebo
Schmitt C, Portron A, Jadidi S, Sarkar N, DiMarchi R
Types of Damages Recoverable in Ozempic Lawsuits Individuals affected by Ozempic may be eligible for various types of compensation